Valspodar-modulated chemotherapy in human ovarian cancer cells SK-OV-3 and MDAH-2774

Maciej Zalewski, Julita Kulbacka, Jolanta Saczko, Małgorzata Drag-Zalesinska, Anna Choromanska

Research output: Contribution to journalArticle

Abstract

Overcoming drug resistance in ovarian cancer is the overarching goal in gynecologic oncology. One way to increase drug cytotoxicity without increasing the drug dose is to simultaneously apply multidrug resistance modulator. Valspodar is the second generation P-glycoprotein 1 modulator capable of reversing multidrug resistance in different cancers. In this study, we evaluated the effect of valspodar and cisplatin co-treatment on cell viability, cell death and oxidative status in ovarian cancer cells. Two human ovarian cancer cell lines SK-OV-3 and MDAH-2774 were treated with cisplatin, valspodar, or cisplatin + valspodar for 24 or 48 hours. Untreated cells were used as control group. Cell viability was evaluated by MTT assay. Cell death was assessed by TUNEL and comet assay. Lipid peroxidation (malondialdehyde) and protein thiol groups were analyzed as oxidative stress markers. The expression of mitochondrial superoxide dismutase (MnSOD) was assessed by immunocytochemistry. Valspodar effectively reduced the resistance of SK-OV-3 cells to cisplatin, as demonstrated by increased oxidative stress, decreased cell viability and increased apoptosis in SK-OV-3 cells co-treated with valspodar and cisplatin compared to other groups. However, valspodar did not significantly affect the resistance of MDAH-2774 cells to cisplatin. Stronger staining for MnSOD in MDAH-2774 vs. SK-OV-3 cells after co-treatment with cisplatin and valspodar may determine the resistance of MDAH-2774 cell line to cisplatin.

Original languageEnglish (US)
Pages (from-to)234-241
Number of pages8
JournalBosnian journal of basic medical sciences
Volume19
Issue number3
DOIs
StatePublished - Aug 20 2019

Fingerprint

Ovarian Neoplasms
Cisplatin
Drug Therapy
Cell Survival
Multiple Drug Resistance
Superoxide Dismutase
Oxidative Stress
Cell Death
Cell Line
Comet Assay
valspodar
In Situ Nick-End Labeling
Malondialdehyde
Drug Resistance
Sulfhydryl Compounds
Pharmaceutical Preparations
Lipid Peroxidation
Immunohistochemistry
Apoptosis
Staining and Labeling

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Valspodar-modulated chemotherapy in human ovarian cancer cells SK-OV-3 and MDAH-2774. / Zalewski, Maciej; Kulbacka, Julita; Saczko, Jolanta; Drag-Zalesinska, Małgorzata; Choromanska, Anna.

In: Bosnian journal of basic medical sciences, Vol. 19, No. 3, 20.08.2019, p. 234-241.

Research output: Contribution to journalArticle

Zalewski, Maciej ; Kulbacka, Julita ; Saczko, Jolanta ; Drag-Zalesinska, Małgorzata ; Choromanska, Anna. / Valspodar-modulated chemotherapy in human ovarian cancer cells SK-OV-3 and MDAH-2774. In: Bosnian journal of basic medical sciences. 2019 ; Vol. 19, No. 3. pp. 234-241.
@article{3999304dac5f448eb8ab8e5430cfcffa,
title = "Valspodar-modulated chemotherapy in human ovarian cancer cells SK-OV-3 and MDAH-2774",
abstract = "Overcoming drug resistance in ovarian cancer is the overarching goal in gynecologic oncology. One way to increase drug cytotoxicity without increasing the drug dose is to simultaneously apply multidrug resistance modulator. Valspodar is the second generation P-glycoprotein 1 modulator capable of reversing multidrug resistance in different cancers. In this study, we evaluated the effect of valspodar and cisplatin co-treatment on cell viability, cell death and oxidative status in ovarian cancer cells. Two human ovarian cancer cell lines SK-OV-3 and MDAH-2774 were treated with cisplatin, valspodar, or cisplatin + valspodar for 24 or 48 hours. Untreated cells were used as control group. Cell viability was evaluated by MTT assay. Cell death was assessed by TUNEL and comet assay. Lipid peroxidation (malondialdehyde) and protein thiol groups were analyzed as oxidative stress markers. The expression of mitochondrial superoxide dismutase (MnSOD) was assessed by immunocytochemistry. Valspodar effectively reduced the resistance of SK-OV-3 cells to cisplatin, as demonstrated by increased oxidative stress, decreased cell viability and increased apoptosis in SK-OV-3 cells co-treated with valspodar and cisplatin compared to other groups. However, valspodar did not significantly affect the resistance of MDAH-2774 cells to cisplatin. Stronger staining for MnSOD in MDAH-2774 vs. SK-OV-3 cells after co-treatment with cisplatin and valspodar may determine the resistance of MDAH-2774 cell line to cisplatin.",
author = "Maciej Zalewski and Julita Kulbacka and Jolanta Saczko and Małgorzata Drag-Zalesinska and Anna Choromanska",
year = "2019",
month = "8",
day = "20",
doi = "10.17305/bjbms.2019.4073",
language = "English (US)",
volume = "19",
pages = "234--241",
journal = "Bosnian Journal of Basic Medical Sciences",
issn = "1512-8601",
publisher = "Association of Basic Medical Sciences Federation of Bosnia and Herzegovina",
number = "3",

}

TY - JOUR

T1 - Valspodar-modulated chemotherapy in human ovarian cancer cells SK-OV-3 and MDAH-2774

AU - Zalewski, Maciej

AU - Kulbacka, Julita

AU - Saczko, Jolanta

AU - Drag-Zalesinska, Małgorzata

AU - Choromanska, Anna

PY - 2019/8/20

Y1 - 2019/8/20

N2 - Overcoming drug resistance in ovarian cancer is the overarching goal in gynecologic oncology. One way to increase drug cytotoxicity without increasing the drug dose is to simultaneously apply multidrug resistance modulator. Valspodar is the second generation P-glycoprotein 1 modulator capable of reversing multidrug resistance in different cancers. In this study, we evaluated the effect of valspodar and cisplatin co-treatment on cell viability, cell death and oxidative status in ovarian cancer cells. Two human ovarian cancer cell lines SK-OV-3 and MDAH-2774 were treated with cisplatin, valspodar, or cisplatin + valspodar for 24 or 48 hours. Untreated cells were used as control group. Cell viability was evaluated by MTT assay. Cell death was assessed by TUNEL and comet assay. Lipid peroxidation (malondialdehyde) and protein thiol groups were analyzed as oxidative stress markers. The expression of mitochondrial superoxide dismutase (MnSOD) was assessed by immunocytochemistry. Valspodar effectively reduced the resistance of SK-OV-3 cells to cisplatin, as demonstrated by increased oxidative stress, decreased cell viability and increased apoptosis in SK-OV-3 cells co-treated with valspodar and cisplatin compared to other groups. However, valspodar did not significantly affect the resistance of MDAH-2774 cells to cisplatin. Stronger staining for MnSOD in MDAH-2774 vs. SK-OV-3 cells after co-treatment with cisplatin and valspodar may determine the resistance of MDAH-2774 cell line to cisplatin.

AB - Overcoming drug resistance in ovarian cancer is the overarching goal in gynecologic oncology. One way to increase drug cytotoxicity without increasing the drug dose is to simultaneously apply multidrug resistance modulator. Valspodar is the second generation P-glycoprotein 1 modulator capable of reversing multidrug resistance in different cancers. In this study, we evaluated the effect of valspodar and cisplatin co-treatment on cell viability, cell death and oxidative status in ovarian cancer cells. Two human ovarian cancer cell lines SK-OV-3 and MDAH-2774 were treated with cisplatin, valspodar, or cisplatin + valspodar for 24 or 48 hours. Untreated cells were used as control group. Cell viability was evaluated by MTT assay. Cell death was assessed by TUNEL and comet assay. Lipid peroxidation (malondialdehyde) and protein thiol groups were analyzed as oxidative stress markers. The expression of mitochondrial superoxide dismutase (MnSOD) was assessed by immunocytochemistry. Valspodar effectively reduced the resistance of SK-OV-3 cells to cisplatin, as demonstrated by increased oxidative stress, decreased cell viability and increased apoptosis in SK-OV-3 cells co-treated with valspodar and cisplatin compared to other groups. However, valspodar did not significantly affect the resistance of MDAH-2774 cells to cisplatin. Stronger staining for MnSOD in MDAH-2774 vs. SK-OV-3 cells after co-treatment with cisplatin and valspodar may determine the resistance of MDAH-2774 cell line to cisplatin.

UR - http://www.scopus.com/inward/record.url?scp=85071712946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071712946&partnerID=8YFLogxK

U2 - 10.17305/bjbms.2019.4073

DO - 10.17305/bjbms.2019.4073

M3 - Article

VL - 19

SP - 234

EP - 241

JO - Bosnian Journal of Basic Medical Sciences

JF - Bosnian Journal of Basic Medical Sciences

SN - 1512-8601

IS - 3

ER -